I just got back my PET/CT results from yesterday. Bad! I have never had so much progression. Little spots, some new, some growing from last time, mostly in thoracic and lung area. Apparently, ribociclib (Kisqali) + exemestane didn't work at all. That is the last of the CDK4/6 inhibitors and ER inhibitors for me.
I haven't talked to my oncologist yet. (Appointment is for next week!) My cancer is indolent. I haven't had any consequences from it. My tumors are small. The problem is that I am on my 5th line of Rx in five years. I have talked to my oncologist about resistance (I have been NEAD twice, so some things have worked, then just stopped working), and she says it is always from mutation -- but I don't have any actionable mutations. I tried to show her research from Dana Farber about other causes of resistance but she said it was not "standard of care" and wouldn't look.
I always said I would go to DF if this happened. I looked at their virtual second opinions and it requires plunking down $2,400 to get started and it says Medicare doesn't cover it. I had a second opinion at MSK before, and it was covered. This seems very impersonal. The sample second opinion doesn't look like what I want.
When I have brought this up before, I recall people saying that I should call instead, that there is another way this works that is better.
Can anyone who has done this give me some advice about how to pursue this? I guess I could also go back to MSK for a second opinion, since they already have my info and I can go in person, but it appears to me that DF has more to offer someone in my situation.
I suppose I should see what my onc says first? I am ER+, PR-, HER2 low. She has said before that the next treatment would be oral chemo, but the last time I brought it up, she said there are other options. I think she was thinking of the HER2 low treatment. She didn't want to talk about it until the results came in.
Perhaps I need a new liquid biopsy to see if anything has changed? I haven't had the ESR1 mutation, but that could change.
Thanks,
Chris